These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12717976)

  • 21. In vitro susceptibility of Actinobaculum schaalii to 12 antimicrobial agents and molecular analysis of fluoroquinolone resistance.
    Cattoir V; Varca A; Greub G; Prod'hom G; Legrand P; Lienhard R
    J Antimicrob Chemother; 2010 Dec; 65(12):2514-7. PubMed ID: 20952417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of gyrA and parC mutations in enterococci from environmental samples with reduced susceptibility to ciprofloxacin.
    Petersen A; Jensen LB
    FEMS Microbiol Lett; 2004 Feb; 231(1):73-6. PubMed ID: 14769469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation between mutation of GyrA and ParC genes and quinolone resistance in Neisseria gonorrhoeae].
    Xie P; Mi ZH; Li Q; Zhang J; Xiao CY
    Zhonghua Nan Ke Xue; 2003; 9(4):275-8. PubMed ID: 12931370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
    Misiurina OIu; Shipitsina EV; Finashutina IuP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
    Mol Gen Mikrobiol Virusol; 2004; (3):3-7. PubMed ID: 15354934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular cloning of the DNA gyrase genes from Methylovorus sp. strain SS1 and the mechanism of intrinsic quinolone resistance in methylotrophic bacteria.
    Kim KS; Kim JH; Kim DY; Kim HJ; Park ST; Kim YM
    Mol Cells; 2005 Dec; 20(3):392-400. PubMed ID: 16404155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.
    Smith HJ; Nichol KA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2002 Jun; 49(6):893-5. PubMed ID: 12039880
    [No Abstract]   [Full Text] [Related]  

  • 28. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanisms for the development of quinolone resistance].
    Kojima M
    Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of and resistance to quinolones.
    Bearden DT; Danziger LH
    Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Present status of infectious keratitis].
    Shimomura Y
    Nippon Ganka Gakkai Zasshi; 2006 Dec; 110(12):941-2. PubMed ID: 17228756
    [No Abstract]   [Full Text] [Related]  

  • 33. [Quinolone use and resistance].
    Oteo J; Campos J
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):201-3. PubMed ID: 15056434
    [No Abstract]   [Full Text] [Related]  

  • 34. Fluoroquinolones: structure and target sites.
    Higgins PG; Fluit AC; Schmitz FJ
    Curr Drug Targets; 2003 Feb; 4(2):181-90. PubMed ID: 12558069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alarmingly High Segregation Frequencies of Quinolone Resistance Alleles within Human and Animal Microbiomes Are Not Explained by Direct Clinical Antibiotic Exposure.
    Field W; Hershberg R
    Genome Biol Evol; 2015 May; 7(6):1743-57. PubMed ID: 26019163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolutionary twist on topoisomerases: conversion of gyrase to topoisomerase IV.
    Neuman KC
    Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22363-4. PubMed ID: 21169503
    [No Abstract]   [Full Text] [Related]  

  • 37. [Fluoroquinolones and problems of molecular mechanism of their action].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2000; 45(8):3-5. PubMed ID: 10989716
    [No Abstract]   [Full Text] [Related]  

  • 38. Preface: forum on biocidal materials & interfaces.
    Schanze KS
    ACS Appl Mater Interfaces; 2011 Aug; 3(8):2807. PubMed ID: 21861525
    [No Abstract]   [Full Text] [Related]  

  • 39. New fluoroquinolones: a class of potent antibiotics.
    De Souza MV
    Mini Rev Med Chem; 2005 Nov; 5(11):1009-17. PubMed ID: 16307530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid identification of bacterial blight strains isolated from cotton in western Kenya using gyrB gene sequence.
    Chepkurui KP; Venneman J; Audenaert K; Kiplagat O; Haesaert G; Gheysen G
    Commun Agric Appl Biol Sci; 2013; 78(3):443-6. PubMed ID: 25151820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.